|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-3-24
|
|
pubmed:abstractText |
Treatment with interferon-alpha (IFN-alpha) may eradicate HCV in most acute hepatitis C patients, thus preventing chronic hepatitis and avoiding less efficacious combination therapy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0168-8278
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
323-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15791696-Acute Disease,
pubmed-meshheading:15791696-Adolescent,
pubmed-meshheading:15791696-Adult,
pubmed-meshheading:15791696-Antiviral Agents,
pubmed-meshheading:15791696-Female,
pubmed-meshheading:15791696-Hepatitis,
pubmed-meshheading:15791696-Hepatitis C,
pubmed-meshheading:15791696-Humans,
pubmed-meshheading:15791696-Interferon-alpha,
pubmed-meshheading:15791696-Male,
pubmed-meshheading:15791696-Patient Compliance,
pubmed-meshheading:15791696-Polyethylene Glycols,
pubmed-meshheading:15791696-Recombinant Proteins,
pubmed-meshheading:15791696-Substance Abuse, Intravenous,
pubmed-meshheading:15791696-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C.
|
|
pubmed:affiliation |
Département de Médecine Communautaire, University Hospitals, Geneva, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
